

Keith Barton – Financial Disclosure – last 5 years – updated 14.03.2025

Consultant: AbbVie Ltd, Advanced Ophthalmic Innovations, Alcon, Allergan, Calilia, Elios Vision, EyeD Pharma, W.L Gore & Associates Inc, iStar Medical, Ivantis Laboratoires Théa, Liquid Medical, Myra Vision, Nova Eye Medical, Ph Pharma, Radiance Therapeutics, Roche, Santen Pharmaceutical Co. Ltd, Sight Sciences, ,

Honorarium Recipient: Abbvie Ltd, Advanced Ophthalmic Innovations, Alcon, JamJoom Pharmaceuticals, Laboratoires Théa, Myra Vision, Santen Pharmaceutical Co. Ltd

Commented [KW1]: These are under confirmed by email to be placed under the consultant category

Stock Shareholder: Aquesys, C-Mer Holdings, Ellios Vision, International Glaucoma Surgery Registry Ltd, Ivantis, MedEther Ophthalmology (Hong Kong) Ltd, Myra Vision, Vision Futures Ltd, Vision Medical Events Ltd,

Patent: National University of Singapore



Mr Keith Barton

Consultant Ophthalmologist

Keith Barton – Financial Disclosure – last 5 years – updated 14.03.2025

Organisation	Consultant	Honorarium Recipient	Stock/ Shares	Patent
AbbVie Limited	x	x		
Advanced Ophthalmic Innovations	x	x		
Alcon	x	x		
Allergan	x			
Aquesys (Actavis)			x	
Calilia	x			
C-mer Holdings			x	
Elios Vision	x		x	
EyeD Pharma	x			
International Glaucoma Registry Ltd			x	
iStar Medical	x			
Ivantis	x		x	
JamJoom Pharmaceuticals		x		
Laboratoires Thea	x	x		
Liquid Medical	x			
MedEther Ophthalmology (Hong Kong) Ltd			x	
Myra Vision	x	x	x	
National University of Singapore				x
Nova Eye Medical	x			
Ph Pharma	x			
Radiance Therapeutics	x			
Roche	x			
Santen Pharmaceutical Co Ltd	x	x		
Sight Sciences	x			
Vision Futures Ltd			x	
Vision Medical Events			x	

Keith Barton – Financial Disclosure – last 5 years – updated 14.03.2025